Meet the CEO
22 September
Meet the CEO
22 September
Carine Punt, CEO of BunyaVax BV
With more than 13 years of experience in the field of R&D drug development and biotech, I was appointed early 2020 as CEO of BunyaVax to contribute to the strategic management and success of the company. It is my ambition to connect my veterinary background and human drug development experiences to support the development of vaccines against emerging bunyavirus related diseases of animals and humans. Starting as a doctor of veterinary medicine (DVM) and a few years in veterinary academics, new challenges and personal development opportunities came my way at Teva Pharmaceuticals from 2008 onwards, focusing on the R&D development of complex generics. Since early 2014 I developed myself further as a senior scientist and European Registered Toxicologist (ERT) at the ambitious and fast growing biotech company ProQR, developing RNA therapies for rare genetic diseases. As a practical, results-driven professional and team player, driven by my curiosity and eagerness to learn, I enjoy turning challenges into opportunities.
BunyaVax
BunyaVax has developed a proprietary technology to attenuate bunyaviruses and uses these technologies to develop live attenuated vaccines that optimally combine efficacy with safety against neglected diseases of animals and humans. The technologies are also being used to develop diagnostic assays of unmatched specificity and sensitivity. BunyaVax prioritizes viral pathogens that affect animal and human health in developing countries.
The current focus of the company is on Rift Valley fever virus (RVFV), a mosquito-transmitted pathogen of ruminants and humans that can affect millions of animals and thousands of humans in single outbreaks. BunyaVax is leading the LARISSA project (www.larissa.online) that is funded and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) (www.cepi.net), which aims to develop a human Rift Valley fever vaccine. In parallel, BunyaVax is developing a vaccine for veterinary use in collaboration with a world-leading animal health company. More information about RVFV and the technology used to develop human and veterinary vaccines is on our website www.Bunyavax.com.
BunyaVax
BunyaVax has developed a proprietary technology to attenuate bunyaviruses and uses these technologies to develop live attenuated vaccines that optimally combine efficacy with safety against neglected diseases of animals and humans. The technologies are also being used to develop diagnostic assays of unmatched specificity and sensitivity. BunyaVax prioritizes viral pathogens that affect animal and human health in developing countries.
The current focus of the company is on Rift Valley fever virus (RVFV), a mosquito-transmitted pathogen of ruminants and humans that can affect millions of animals and thousands of humans in single outbreaks. BunyaVax is leading the LARISSA project (www.larissa.online) that is funded and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) (www.cepi.net), which aims to develop a human Rift Valley fever vaccine. In parallel, BunyaVax is developing a vaccine for veterinary use in collaboration with a world-leading animal health company. More information about RVFV and the technology used to develop human and veterinary vaccines is on our website www.Bunyavax.com.
| Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | | |
© Copyright 2020 by Hyphen Projects